Anti-d immunoglobulin - intramuscular

Concise Prescribing Info
Dosage Details
Transfusion of D-positive blood components to rhesus-negative women of child-bearing potential
Adult: 125 units/ml of transferred cells.

Prevent formation of antibodies against fetal rhesus-positive RBCs in a rhesus-negative mother during childbirth, abortion or certain other sensitising events
Adult: 500 units as soon as possible after birth. An additional dose may be required depending on the amount of transplacental bleeding as assessed by the Kleihauer test; for bleeds >4 ml, an additional 125 units for each ml of RBCs will be required.

Routine antenatal prophylaxis
Adult: 2 doses of 500 units to be given at wk 28th and 34th of gestation.

Idiopathic thrombocytopenic purpura
Adult: Initially, 250 units/kg, may be given in 2 divided doses on separate days. Maintenance doses: 125-300 units/kg depending on the clinical response.
Splenectomised or rhesus-negative patients, in whom the resultant haemolysis may exacerbate pre-existing anaemia. Hypersensitivity.
Special Precautions
For postpartum usage, it is to be used only for maternal admin. Not for rhesus-positive individuals. Patients should be observed for 20 minutes after admin.
Adverse Reactions
Hypersensitivity reactions such as hives, wheezing, urticaria, Pain and tenderness at inj site. Fever, chills, nausea, facial flushing, headache.
Potentially Fatal: Intravascular haemolysis. Anaphylaxis reactions.
IM/IV/Parenteral: C
Drug Interactions
Live vaccines should only be admin at least 3 mth after the last dose of immunoglobulin admin.
Lab Interference
May affect the results of blood typing and antibody testing such as Coomb's test or antiglobulin test.
Description: Anti-D immunoglobulin prevents a rhesus-negative mother from actively forming antibodies to foetal rhesus-positive RBCs that may pass into the maternal circulation during childbirth, abortion, or certain other sensitising events. It is also used in idiopathic thrombocytopenic purpura to prevent excessive bleeding.
Disclaimer: This information is independently developed by MIMS based on Anti-D Immunoglobulins from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in